INTRODUCTION
Mitral regurgitation (MR) is a common heart valve disease, in which the mitral valve fails to close during the left ventricular systole and causes blood to flow from the left ventricle to the left atrium, including primary (degenerative) MR and secondary (functional) MR.[1] With the gradual aging of the global population, the number of MR patients has shown an upward trend year by year and the annual mortality rate was as high as 34%.[2] The treatment methods of MR mainly include drug therapy, surgery and percutaneous interventional therapy. Drug therapy can only improve the symptoms of the patient, but cannot prolong the survival time; the surgical operation includes mainly valve repair and valve replacement, which is considered to be the standard treatment for MR. Percutaneous intervention technology has become a supplementary treatment option for high-risk MR patients who cannot withstand the blow of surgery. [3] After 30 years of development, Minimally invasive cardiac surgery (MICS) technology reduces the trauma caused by the operation itself in the case of providing the same curative effect as the C-MVS operation. In recent years, there have been studies that directly compared different minimally invasive options, such as R-MVS, 3D-MVS, T-MVS, M-MVS, C-MVS, etc., but lack of network meta-analysis research. This study has been used to systematically evaluates the respective advantages and mid-term efficacy of different surgical procedures, discuss the best minimally invasive MV surgery and provide clinical reference for the majority of cardiac surgery colleagues.
MATERIALS AND METHODS
Patient and public involvement No patients were involved.